ALNYLAM PHARMACEUTICALS, INC.

For the period ended Dec 31, 2025. Filed Feb 12, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 12, 2026

ALNY$156.61+0.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, on February 12, 2026.

ALNYLAM PHARMACEUTICALS, INC.
By:	/s/ Yvonne L. Greenstreet, M.D.
	Yvonne L. Greenstreet, M.D.
	Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, the Report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated as of February 12, 2026.

Stuart A. Arbuckle
Name	Title
/s/ Yvonne L. Greenstreet, M.D.	Director and Chief Executive Officer
Yvonne L. Greenstreet, M.D.	(Principal Executive Officer)
/s/ Jeffrey V. Poulton	Executive Vice President, Chief Financial Officer
Jeffrey V. Poulton	(Principal Financial and Accounting Officer)
/s/ Stuart A. Arbuckle	Director
/s/ Dennis A. Ausiello, M.D.	Director
Dennis A. Ausiello, M.D.
/s/ Olivier Brandicourt, M.D.	Director
Olivier Brandicourt, M.D.
/s/ Margaret A. Hamburg, M.D.	Director
Margaret A. Hamburg, M.D.
/s/ Peter N. Kellogg	Director
Peter N. Kellogg
/s/ David E.I. Pyott	Director
David E.I. Pyott
/s/ Colleen F. Reitan	Director
Colleen F. Reitan
/s/ Amy W. Schulman	Director
Amy W. Schulman
/s/ Elliott Sigal, M.D., Ph.D.	Director
Elliott Sigal, M.D., Ph.D.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.